Viridian Therapeutics to Participate in Upcoming May Investor Conferences
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target lowered by analysts at HC Wainwright from $37.00 to $27.00. They now have a "buy" rating on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $36.00 to $31.00. They now have an "outperform" rating on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) was downgraded by analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.